公开(公告)号：US07947827B2

公开(公告)日：2011-05-24

申请号：US11825146

申请日：2007-07-02

申请人： George S. Bailey, Jr. ,  Carole Jubert

发明人： George S. Bailey, Jr. ,  Carole Jubert

IPC分类号： C07B47/00 ,  C07D487/22

CPC分类号： A61K31/555 ,  C07D487/22

摘要： Pharmaceutical formulation for the prophylaxis, pretreatment and treatment of a poisoning caused by exposure to (either singly or as a mixture of agents) organophosphorus cholinesterase inhibitors, vesicating agents, polycyclic aromatic hydrocarbons, and aflatoxin B1. This invention is characterized by active substance comprised of a metaloporphyrin molecule with an associated metal moiety (Cu, Mg) of suitable purity and chemical composition to provide a bioavailable oral dosage form to attain predictable concentrations in target tissues and bodily fluids (plasma, bronchial secretions, etc.) sufficient to counteract the effects of toxic substances through chemical complexation or catalysis of toxin degradation. Although these metaloporphyrins are semisynthetic products of chlorophyll, the preferred starting material is chlorophyll a (Chla) extracted and purified from Spirulina pacifica or other sources. A specific method is invented to achieve a critical combination of purity and yield beyond those currently available.

摘要翻译： 用于预防，预处理和治疗由暴露于（单独或作为混合物）的有机磷胆碱酯酶抑制剂，泡沫剂，多环芳烃和黄曲霉毒素B1引起的中毒的药物制剂。 本发明的特征在于活性物质由具有适当纯度和化学组成的相关金属部分（Cu，Mg）的金属卟啉分子组成，以提供生物可利用的口服剂型，以在靶组织和体液（血浆，支气管分泌物）中获得可预测的浓度 等）足以通过化学络合或催化毒素降解来抵消有毒物质的影响。 虽然这些金属卟啉是叶绿素的半合成产物，但优选的起始物质是从螺旋藻或其他来源提取和纯化的叶绿素a（Chla）。 发明了一种具体的方法来实现超过目前可获得的纯度和产量的关键组合。